Previous studies have reported estimated cumulative lifetime risk percentages based on APOE genotype in individuals with a family-history of AD to be 30%, 46% and 61% for ε3/3 homozygotes, ε3/4 heterozygotes and ε4/4 homozygotes, respectively [5]. This evidence concerns the gene APOE and Alzheimer disease.